Evidence map›Paper›PMID 41717451›Full record

ArticleHemaSphere2026

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

Noemí Puig, Cristina Agulló, Bruno Paiva, María-Teresa Cedena, Laura Rosiñol, Teresa Contreras, Joaquín Martínez-López, Albert Oriol, María-Jesús Blanchard, Rafael Ríos-Tamayo and 15 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Noemí PuigHematology Department IBSAL, Instituto de Biología Molecular y Celular del Cáncer-Consejo Superior de Investigaciones Científicas (IBMCC-CSIC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Salamanca Spain.ORCID https://orcid.org/0000-0001-7535-3861
Cristina AgullóClinical Biochemistry Department Hospital Universitario de Salamanca Salamanca Spain.
Bruno PaivaClínica Universidad de Navarra, CUN, CIMA, IDISNA, CIBERONC CB16/12/00369 Pamplona Spain.
María-Teresa CedenaHospital Universitario 12 de Octubre, Complutense University, i + 12, CNIO, CIBERONC, CB16/12/00369 Madrid Spain.
Laura RosiñolHospital Clinic, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS) Barcelona Spain.
Teresa ContrerasClinical Biochemistry Department Hospital Universitario de Salamanca Salamanca Spain.
Joaquín Martínez-LópezHospital Universitario 12 de Octubre, Complutense University, i + 12, CNIO, CIBERONC, CB16/12/00369 Madrid Spain.
Albert OriolInstitut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol Barcelona Spain.
María-Jesús BlanchardHematology Department Hospital Ramón y Cajal Madrid Spain.
Rafael Ríos-TamayoHospital Universitario Virgen de las Nievels, Ibs Granada Spain.
Anna SuredaInstitut Catalá d'Oncologia- l'Hospitalet, IDIBELL, Universitat de Barcelona Barcelona Spain.
Sunil LakhwaniHospital Universitario de Canarias Santa Cruz de Tenerife Spain.ORCID https://orcid.org/0000-0003-1984-4839
Javier de la RubiaHematology Department University Hospital La Fe and School of Medicine and Dentistry, Catholic University of Valencia, CIBERONC CD16/12/00284 Valencia Spain.
Valentín CabañasHospital Universitario Virgen de la Arrixaca, IMIB Murcia Spain.
Felipe de ArribaHospital Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia Murcia Spain.ORCID https://orcid.org/0000-0002-4451-1318
Miguel ParicioHospital Clínico Universitario Lozano Blesa, Instituto Investigacion Sanitaria Aragon Zaragoza Spain.
María-Belén IñigoHospital Clínico San Carlos Madrid Spain.
Verónica González-CalleHematology Department IBSAL, Instituto de Biología Molecular y Celular del Cáncer-Consejo Superior de Investigaciones Científicas (IBMCC-CSIC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Salamanca Spain.
Enrique M OcioHospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria Santander Spain.
Sergio CastroClinical Biochemistry Department Hospital Universitario de Salamanca Salamanca Spain.
Joan BargayHospital Universitario Son Llàtzer, IdIsBa Palma de Mallorca Spain.
Joan BladéHospital Clinic, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS) Barcelona Spain.
Jesús F San MiguelClínica Universidad de Navarra, CUN, CIMA, IDISNA, CIBERONC CB16/12/00369 Pamplona Spain.
Juan-José LahuertaHospital Universitario 12 de Octubre, Complutense University, i + 12, CNIO, CIBERONC, CB16/12/00369 Madrid Spain.
María V MateosHematology Department IBSAL, Instituto de Biología Molecular y Celular del Cáncer-Consejo Superior de Investigaciones Científicas (IBMCC-CSIC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Salamanca Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41717451
PMCPMC12915834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.